2. Scottish Executive Health Department. Health in Scotland 2001. Edinburgh: The Executive; 2002. [cited 12 Nov 2003]. Available from url: http://www.scotland.gov.uk/library5/health/his01-00.asp

3. Scottish Executive. 2001 Scottish social statistics. Edinburgh: The Executive; 2002. [cited 12 Nov 2003]. Available from url: http://www.scotland.gov.uk/stats/sss/docs/sss00-01.asp

4. Torgerson D, Bell-Syer S. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001;285(22):2891-7. [section 1] [section 3] [section 5]

5. Compston J, Cooper C, Kanis J. Bone densitometry in clinical practice. BMJ 1995;310:1507-10.

6. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997;7:390-406.

7. Scottish Intercollegiate Guidelines Network (SIGN). Prevention and management of hip fracture in older people. Edinburgh: SIGN; 2002. (SIGN publication no. 56). [section 1] [section 2]

8. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994;843:1-129.

9. Kanis J, Johnell O, Oden A, De Laet C, Mellstrom D. Diagnosis of osteoporosis and fracture threshold in men. Calcif Tissue Int 2001;69(4):218-21.

10. Melton L, Orwoll E, Wasnich R. Does bone density predict fractures comparably in men and women? Osteoporos Int 2001;12(9):707-9.

11. Chapman KM, Chan MW. Focus groups: their role in developing calcium-related education materials. J Hum Nutr Dietetics 1995;8:363-7.

12. Fox-Young S, Sheehan M, O'Connor V, Cragg C, Del Mar C. Women's perceptions and experience of menopause: a focus group study. J Psychosom Obstet Gynaecol 1995;16:215-21. [section 1.4.1] [section 1.4.4]

13. Hunter M, O'Dea I. Perception of future health risks in mid-aged women: estimate with and without behavioural changes and hormone replacement therapy. Maturitas 1999;33:37-43. [section 1.4.1] [section 1.4.4]

14. Liao KL, Hunter M, Weinman J. Health-related behaviours and their correlates in a general population sample of 45-year old women. Psychol Health 1995;10:171-84.

15. Ribeiro V, Blakeley J, Laryea M. Women's knowledge and practices regarding the prevention and treatment of osteoporosis. Health Care Women Int 2000;21:346-53.

16. Paier GS. Specter of the crone: the experience of vertebral fracture. Adv Nurs Sci 1996;18:27-36.

17. Quantock C, Beynon J. Evaluating an osteoporosis service using a focus group. Nurs Stand 1997;11:45-7. [section 1.4.3] [section 1.4.4]

18. Zimmer Z, Myers A. Receptivity to protective garments among the elderly. J Aging Health 1997;9:355-72.

19. McPhail G. Menopause as an issue for women with breast cancer. Cancer Nurs 1999;22:164-71.

20. Castelo-Branco C, Figueras F, Sanjuan A, Vicente JJ, nez de Osaba Mart MJ, Pons F, et al. Long-term compliance with estrogen replacement therapy in surgical postmenopausal women: benefits to bone and analysis of factors associated with discontinuation. Menopause 1999;6:307-11.

21. Griffiths F. Women's decision making about hormone replacement therapy balanced being in control with fear, uncertainty, and dislike of medications. Soc Sci Med 1999;49:469-81.

22. Tosteson AN, Gabriel SE, Kneeland TS, Moncur MM, Manganiello PD, Schiff I, et al. Has the impact of hormone replacement therapy on health-related quality of life been undervalued? J Womens Health Gender Based Med 2000;9:119-30.

23. Chandler JM, Martin AR, Girman CD, Ross P, Love-Mcclung B, Yawn BP. Reliability of an Osteoporosis-Targeted Quality of Life Survey instrument for use in the community: OPTQoL. Osteoporos Int 1998;8:127-35.

24. Kessenich CR, Guyatt GH. Domains of health-related quality of life in elderly women with osteoporosis. J Gerontol Nurs 1998;24:7-13. [section 1.4.5] [section 1.4.6]

25. Robinson S. Transitions in the lives of elderly women who have sustained hip fractures. J Adv Nurs 1999;30:1341-8.

26. Slauenwhite CA, Simpson P. Patient and family perspectives on early discharge and care of the older adult undergoing fractured hip rehabilitation. Orthop Nurs 1998;17:30-6.

27. Tierney AJ, Vallis J. An examination of hip fracture outcomes. Clin Effect Nurs 1998;2:197-204.

28. Hallstrom I, Elander G, Rooke L. Pain and nutrition as experienced by patients with hip fracture. J Clin Nurs 2000;9:639-46.

29. Hallstrom I. Quality improvement in the care of patients with hip fracture. Int J Health Care Qual Assur 2001;14:29-33.

30. Health Education Board for Scotland. The construction of the risks of falling in older people: lay and professional perspectives. Edinburgh: The Board. [cited 13 Nov 2003]. Available from url: http://www.hebs.scot.nhs.uk/services/pubs/pubfulltext.cfm?TxtTCode=287&catnav=1&connav=0.

31. Guideline for the prevention of falls in older persons. American Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic Surgeons Panel on Falls Prevention. J Am Geriatr Soc 2001;49:664-72. [section 2] [section 4]

32. Nelson H, Morris C, Kraemer D, Mahon S, Carney N, Nygren P. Osteoporosis in postmenopausal women: diagnosis and monitoring. Portland: Oregon Health & Science University Evidence-based Practice Center; 2001. [cited 13 Nov 2003]. Available from url: http://hstat.nlm.nih.gov/hq/Hquest/db/local.epc.er.erta28/screen/TocDisplay/s/52762/action/Toc [section 2] [section 3.3.1] [section 3.5] [section 3.5.1] [section 3.8] [section 6] [section 7]

33. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-3.

34. van Staa T, Leufkens H, Cooper C. Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos Int 2002;13:624-9.

35. Ross P, Genant H, Davis J, Miller P, Wasnich R. Predicting vertebral fracture incidence from prevalent fractures and bone density among non- black, osteoporotic women. Osteoporosis Int 1993;3:120-6. [section 2] [section 6.1.4] [section 6.2]

36. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41. [section 2] [section 6.1.4] [section 6.3.1]

37. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82. [section 2] [section 6.1.4] [section 6.4.1]

38. Snelling A, Crespo C, Schaeffer M, Smith S, Walbourn L. Modifiable and nonmodifiable factors associated with osteoporosis in postmenopausal women: results from the Third National Health and Nutrition Examination Survey, 1988-1994. J Womens Health Gend Based Med 2001;10(1):57-65. [section 2.4.1] [section 2.4.3] [section 2.4.5]

39. Melton L. How many women have osteoporosis now? J Bone Miner Res 1995;10(2):175-7.

40. Ballard PA, Purdie DW, Langton CM, Steel SA, Mussurakis S. Prevalence of osteoporosis and related risk factors in UK women in the seventh decade: osteoporosis case finding by clinical referral criteria or predictive model? Osteoporos Int 1998;8:535-9.

41. Hannan MT, Felson DT, Dawson-Hughes B, Tucker KL, Cupples LA, Wilson PW, et al. Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res 2000;15:710-20. [section 2.4.2] [section 2.4.4] [section 2.5.2]

42. Francis R, Peacock M, Marshall D, Horsman A, Aaron J. Spinal osteoporosis in men. Bone Miner 1989;5(3):347-57. [section 2] [section 6]

43. Baillie S, Davison C, Johnson F, Francis R. Pathogenesis of vertebral crush fractures in men. Age Ageing 1992;21(2):139-41. [section 2] [section 6]

44. Aloia J, Vaswan IA, Yeh J, Flaster E. Risk for osteoporosis in black women. Calcif Tissue Int 1996;59(6):415-23.

45. Melton L, Bryant S, Wahner H, O'Fallon W, Malkasian G, Judd H, et al. Influence of breastfeeding and other reproductive factors on bone mass later in life. Osteoporos Int 1993;3(2):76-83.

46. Ravn P, Cizza G, Bjarnason NH, Thompson D, Daley M, Wasnich RD, et al. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res 1999;14:1622-7. [section 2.4.4] [section 2.5.1]

47. Soroko S, Barrett-Connor E, Edelstein S, Kritz-Silverstein D. Family history of osteoporosis and bone mineral density at the axial skeleton: the Rancho Bernardo Study. J Bone Miner Res 1994;9(6):761-9.

48. Omland LM, Tell GS, Ofjord S, Skag A. Risk factors for low bone mineral density among a large group of Norwegian women with fractures. Eur J Epidemiol 2000;16:223-9. [section 2.5.1] [section 2.5.4]

49. Law MR, Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ 1997;315:841-6.

50. Cornuz J, Feskanich D, Willett W, Colditz G. Smoking, smoking cessation, and risk of hip fracture in women. Am J Med 1999;106:311-4.

51. Rubin LA, Hawker GA, Peltekova VD, Fielding LJ, Ridout R, Cole DE. Determinants of peak bone mass: clinical and genetic analyses in a young female Canadian cohort. J Bone Miner Res 1999; 14: 633-43.

52. Bidoli E, Schinella D, Franceschi S. Physical activity and bone mineral density in Italian middle-aged women. Eur J Epidemiol 1998;14(2):153-7.

53. Coupland C, Cliffe S, Bassey E, Grainge M, Hosking D, Chilvers C. Habitual physical activity and bone mineral density in postmenopausal women in England. Int J Epidemiol 1999;28(2):241-6.

54. Nguyen TV, Center JR, Eisman JA. Osteoporosis in elderly men and women: effects of dietary calcium, physical activity, and body mass index. J Bone Miner Res 2000;15:322-31.

55. New SA, Bolton-Smith C, Grubb DA, Reid DM. Nutritional influences on bone mineral density: A cross-sectional study in premenopausal women. Am J Clin Nutr 1997;65:1831-9.

56. Melin AL, Wilske J, Ringertz H, Saaf M. Vitamin D status, parathyroid function and femoral bone density in an elderly Swedish population living at home. Aging (Milano) 1999;11:200-7.

57. Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid I. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ 1991;303(6796):220.

58. Gbolade B, Ellis S, Murby B, Randall S, Kirkman R. Bone density in long term users of depot medroxyprogesterone acetate. Br J Obstet Gynaecol 1998;105(7):790-4.

59. Petitti DB, Piaggio G, Mehta S, Cravioto MC, Meirik O. Steroid hormone contraception and bone mineral density: A cross-sectional study in an international population. Obstet Gynecol 2000; 95: 736-44.

60. Lydick E, Cook K, Turpin J, Melton M, Stine R, Byrnes C. Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. Am J Manag Care 1998;4(1):37-48. [section 2.7.1] [section 2.7.2]

61. Burger H, de Laet C, Weel A, Hofman A, Pols H. Added value of bone mineral density in hip fracture risk scores. Bone 1999;25(3):369-74.

62. Martin JC. Appendicular measurements in screening women for low axial bone mineral density. Br J Radiol 1996;69:234-40.

63. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.

64. Garton M, Robertson E, Gilbert F, Gomersall L, DM R. Can radiologists detect osteopenia on plain radiographs? Clin Radiol 1994;49(2):118-22.

65. Masud T, Mootoosamy I, McCloskey E, O'Sullivan M, Whitby E, King D, et al. Assessment of osteopenia from spine radiographs using two different methods: the Chingford Study. Br J Radiol 1996;69(821):451-6.

66. Genant H, Wu C, van Kuijk C, Nevitt M. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8(9):1137-48.

67. Adams JE, Ring F, Eastell R. Position statement on the use of peripheral x-ray absorptiometry in the management of osteoporosis. London: National Osteoporosis Society; 2001. [cited 18 Nov 2003]. Available from url: http://www.nos.org.uk/PDF/PDXAstatement.pdf

68. Abrahamsen B, Stilgren L, Hermann A, Tofteng C, Barehholdt O, Vestergaard P. Discordance between changes in bone mineral density measured at different skeletal sites in postmenopausal women - implications for assessment of bone loss and response to therapy: the Danish Osteoporosis Prevention Study. J Bone Miner Res 2001;16:1212-9.

69. Cummings S, Black D, Nevitt M, Browner W, Cauley J, Ensrud K. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72-5.

70. Patel R, Blake GM, Rymer J, Fogelman I. Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women. Osteoporos Int 2000;11(1):68-75.

71. Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. JAMA 2000;283:1318-21.

72. Zmuda JM, Cauley JA, Glynn NW, Finkelstein JS. Posterior-anterior and lateral dual-energy x-ray absorptiometry for the assessment of vertebral osteoporosis and bone loss among older men. J Bone Miner Res 2000;15:1417-24.

73. Blake GM, Herd RJM, Fogelman I. A longitudinal study of supine lateral DXA of the lumbar spine: a comparison with posteroanterior spine, hip and total-body DXA. Osteoporos Int 1996;6:462-70.

74. De Laet C. Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ 1997;315:221-5.

75. De Laet C. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res 1998;13:1587-93.

76. Doherty D, Sanders K, Kotowicz M, Prince R. Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women. Osteoporos Int 2001;12(1):16-23.

77. Kanis J, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001;12(5):417-27.

78. Klotzbuecher C, Ross P, Landsman P, Abbott T, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721-39. [section 3] [section 6.1.4] [section 6.4]

79. Genant H, Li J, Wu C, Shepherd J. Vertebral fractures in osteoporosis: a new method for clinical assessment. J Clin Densitom 2000;3(3):281-90.

80. Rea J, Li J, Blake G, Steiger P, Genant H, Fogelman I. Visual assessment of vertebral deformity by X-ray absorptiometry: a highly predictive method to exclude vertebral deformity. Osteoporos Int 2000;11(8):660-8.

81. National Osteoporosis Society. Accidents, falls, fractures and osteoporosis: a strategy for primary care groups and local health groups. London: The Society; 2000. [section 3] [section 8]

82. Garnero P. Markers of bone turnover for the prediction of fracture risk. Osteoporos Int 2000;11:S55-65.

83. Bjarnason N, Christiansen C. Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone 2000;26:561-9.

84. Dresner-Pollak R, Mayer M, Hochner-Celiniker D. The decrease in serum bone-specific alkaline phosphatase predicts bone mineral density response to hormone replacement therapy in early postmenopausal women. Calcif Tissue Int 2000;66:104-7.

85. Hochberg M, Greenspan S, Wasnich R, Miller P, Thompson D, Ross P. Changes in bone density and turnover explain the reductions in incidence of non-vertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87:1586-92.

86. Ernst E. Exercise for female osteoporosis. A systematic review of randomised clinical trials. Sports Med 1998;25:359-68.

87. Kelley G. Aerobic exercise and lumbar spine bone mineral density in postmenopausal women: a meta- analysis. J Am Geriatr Soc 1998;46:143-52.

88. Kelley GA, Kelley KS, Tran ZV. Resistance training and bone mineral density in women: a meta-analysis of controlled trials. Am J Phys Med Rehabil 2001;80:65-77.

89. Mazzeo R, Cavanagh P, Evans W, Fiatarone M, Hagberg J, Mcauley E, et al. Exercise and physical activity for older adults: ACSM position stand. Med Sci Sports Exerc 1998;30(6):992-1008.

90. Chartered Society of Physiotherapy. Physiotherapy guidelines for the management of osteoporosis. London: The Society; 2002. [section 4] [section 6]

91. Heaney RP. Calcium, dairy products and osteoporosis. J Am Coll Nutr 2000;19:83S-99S.

92. Weinsier RL, Krumdieck CL. Dairy foods and bone health: examination of the evidence. Am J Clin Nutr 2000;72:681-9.

93. Cumming RG, Nevitt MC. Calcium for prevention of osteoporotic fractures in postmenopausal women. J Bone Miner Res 1997;12:1321-9.

94. Committee on Medical Aspects of Food and Nutrition Policy. Working Group on the Nutritional Status of the Population. Subgroup on Bone Health. Nutrition and bone health: with particular reference to calcium and vitamin D. London: Stationery Office; 1998. (Report on health and social subjects No. 49). [section 4.3.1] [section 4.3.2]

95. Hillier S, Cooper C, Kellingray S, Russell G, Hughes H, Coggon D. Fluoride in drinking water and risk of hip fracture in the UK: a case-control study. Lancet 2000;355:265-9.

96. McDonagh MS, Whiting PF, Wilson PM, Sutton AJ, Chestnutt I, Cooper J. Systematic review of water fluoridation. BMJ 2000;321:844-5.

97. Phipps K. Community water fluoridation, bone mineral density, and fractures: prospective study of effects in older women. BMJ 2000;321:860-4.

98. Kroger H, Alhava E, Honkanen R, Tuppurainen M, Saarikoski S. The effect of fluoridated drinking water on axial bone mineral density-a population-based study. Bone Miner 1994;27(1):33-41.

99. Adami S. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years. Osteoporos Int 1997;7:119-25.

100. Gennari C. Effect of ipriflavone - a synthetic derivative of natural isoflavones - on bone mass loss in the early years after menopause. Menopause 1998;5:9-15.

101. Alexandersen P, Toussaint A, Christiansen C, Devogelaer J, Roux C, Fechtenbaum J. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA 2001;285(11):1482-8.

102. Hope S, Rees M. Why British women start and stop hormone replacement therapy. J Br Meno Soc 1995;1:26-8.

103. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Writing Group for the Women's Health Initiative Investigators. JAMA 2002;288(3):366-8. [section 5.1] [section 5.2]

104. Torgerson D, Bell-Syer S. Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. BMC Musculoskelet Disord 2001;2(1):7.

105. Grady D, Cummings S. Postmenopausal hormone therapy for prevention of fractures: how good is the evidence? JAMA 2001;285(22):2909-10.

106. Lufkin E, Wahner H, O'Fallon W, Hodgson S, Kotowicz M, Lane A. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117:1-9. [section 5] [section 6.1.4] [section 6.3.2]

107. Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998;338:485-92.

108. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-59.

109. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.

110. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-45. [section 5] [section 6.1.4] [section 6.3.3]

111. Scottish Intercollegiate Guidelines Network (SIGN). Prophylaxis of venous thromboembolism. Edinburgh: SIGN; 2002. (SIGN publication No. 62).

112. Weiderpass E, Adami H, Baron J, Magnusson C, Bergstrom R, Lindgren A. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131-7.

113. Lethaby A, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding (Cochrane Review). In: The Cochrane Library, Issue 3, Oxford: Update Software.

114. Herrington D, Reboussin D, Brosnihan K, Sharp P, Shumaker S, Snyder T. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343(8):522-9.

115. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;360(9337):942-4.

116. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344(5):333-40. [section 6.1.4] [section 6.4.1] [section 6.5] [section 6.5.1]

117. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52. [section 6.1.4] [section 6.2] [section 6.2.1]

118. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91. [section 6.1.4] [section 6.2] [section 6.2.1]

119. Watts N, Harris S, Genant H, Wasnich R, Miller P, Jackson R. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-9. [section 6.1.4] [section 6.2] [section 6.2.1]

120. Liberman U, Weiss S, Broll J, Minne H, Quan H, Bell N. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-43.

121. Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76.

122. Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 1999;9:461-8.

123. Gehlbach S, Bigelow C, Heimisdottir M, May S, Walker M, Kirkwood J. Recognition of vertebral fracture in a clinical setting. Osteoporos Int 2000;11:577-82.

124. Brown J, Kendler D, McClung M, Emkey R, Adachi J, Bolognese M. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71(2):103-11.

125. National Health and Nutrition Examination Survey. [cited 19 Nov 2003]. Available from url: http://www.cdc.gov/nchs/nhanes.htm

126. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000;12:1-12. [section 6.3.1] [section 6.6.1]

127. Chapuy M, Arlot M, Duboeuf F, Brun J, Crouzet B, Arnaud S. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637-42.

128. Center J, Nguyen T, Schneider D, Sambrook P, Elsman J. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-82.

129. Diamond T, Thornley S, Sekel R, Smerdely P. Hip fracture in elderly men: prognostic factors and outcomes. Med J Aust 1997;167:412-5.

130. Forsen L, Sogaard A, Meyer H, Edna T, Kopjar B. Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos Int 1999;10:73-8.

131. Myers A, Robinson E, Van Natta M, Michelson J, Collins K, Baker S. Hip fractures among the elderly: factors associated with in-hospital mortality. Am J Epidemiol 1991;134:1128-37.

132. Selby PL, Davies M, Adams JE. Do men and women fracture bones at similar bone densities? Osteoporos Int 2000;11(2):153-7.

133. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604-10.

134. Bone and Tooth Society of Great Britain. National Osteoporosis Society. Royal College of Physicians. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. London: Royal College of Physicians; 2002. [cited 19 Nov 2003]. Available from url: http://www.nos.org.uk/PDF/Glucocorticoid.pdf

135. Harris S, Eriksen E, Davidson M, Ettinger M, Moffett A, Baylink D. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab
2001;86:1890-7.

136. Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 2000;85:720-6.

137. Wimalawansa S. Combined therapies with calcitonin and corticosteroids, or bisphosphonate, for treatment of hypercalcemia of malignancy. J Bone Miner Res 1997;15(3):160-4.

138. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2001;85:3109-15.

139. Hochberg M, Ross P, Black D, Cummings S, Genant H, Nevitt M. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 1999;42:1246-54. [section 5] [section 6]

140. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85:231-6.

141. World Health Organization. Cancer pain relief. 2nd ed. Geneva: The Organization; 1996.

142. Lyritis G, Paspati I, Karachalios T, Ioakimidis D, Skarantavos G, Lyritis P. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. Acta Orthop Scand Suppl 1997;275:112-4. [section 6.11.1] [section 6.11.2]

143. Malmros B, Mortensen L, Jensen M, Charles P. Positive effects of physiotherapy on chronic pain and performance in osteoporosis. Osteoporos Int 1998;8:215-21.

144. Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.

145. Lieberman I, Dudeney S, Reinhardt M, Bell G. Initial outcome and efficacy of “kyphoplasty” in the treatment of painful osteoporotic vertebral compression fractures. Spine 2002;27:548.

146. Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2002;6(29):1-146. [cited 25 Nov 2003]. Available from url: http://www.ncchta.org/fullmono/mon629.pdf [section 7] [section 7.2]

147. Brown MA, Bradlow J. Cost effectiveness of bone density measurements. J Brit Meno Soc 2001; 7: 130-5.

148. Garton MJ, Cooper C, Reid DM. Perimenopausal bone density screening: will it help prevent osteoporosis? Maturitas 1997; 26: 35-43.

149. Food Standards Agency. McCance and Widdowson's the composition of foods. 6th summary ed. Cambridge: Royal Society of Chemistry; 2002.